Expresses the sense of the House of Representatives that the Centers for Medicare and Medicaid Services should: (1) begin an immediate reconsideration of the final National Coverage Determination on the Use of Erythropoiesis Stimulating Agents in Cancer and Related Neoplastic Conditions; (2) consult with members of the clinical oncology community to determine appropriate revisions to such Determination; and (3) implement appropriate revisions to such Determination as soon as feasible and provide a briefing to Congress in advance of announcing such changes.